Atorvastatin Interactions

Red yeast rice naturally contains monacolin K, which is chemically identical to the prescription statin lovastatin. Combining it with atorvastatin effectively stacks two statins, sharply increasing the risk of myopathy, rhabdomyolysis, and liver injury.

Combining high-dose niacin (1-2 g/day, typically extended-release) with atorvastatin or other statins increases the risk of myopathy and rhabdomyolysis. The HPS2-THRIVE trial documented a fourfold excess of myopathy when extended-release niacin was added to simvastatin-based therapy, and the AIM-HIGH trial showed no cardiovascular benefit from this combination.

Grapefruit can increase atorvastatin levels, raising risk of side effects.

Seville (bitter) orange contains the same furanocoumarins as grapefruit, including bergamottin and 6',7'-dihydroxybergamottin, which irreversibly inhibit intestinal CYP3A4. A landmark crossover study showed Seville orange juice raised felodipine AUC by 76%, comparable to grapefruit, and atorvastatin shares the same CYP3A4 metabolic pathway, raising the risk of statin-induced myopathy.

Atorvastatin inhibits HMG-CoA reductase, the same upstream enzyme required to synthesize coenzyme Q10 (ubiquinone). Plasma CoQ10 levels can drop by 30-40% with atorvastatin therapy, and the resulting mitochondrial dysfunction is one proposed mechanism for statin-associated muscle symptoms.

Berberine inhibits CYP3A4 in vitro and can raise plasma levels of CYP3A4 substrates, including atorvastatin, which may increase the risk of muscle pain, liver enzyme elevation, and rhabdomyolysis. The interaction direction is complex — some animal data also show induction — but co-use is unpredictable.

St. John's wort potently induces hepatic and intestinal CYP3A4, accelerating atorvastatin's first-pass metabolism. A controlled study showed roughly a 12% drop in atorvastatin AUC and meaningful increases in LDL and total cholesterol over 4 weeks of co-administration.

Vitamin D's active metabolite (calcitriol) can induce CYP3A4, which metabolizes atorvastatin. Small studies show vitamin D supplementation may reduce atorvastatin and metabolite plasma levels by up to ~55%, although LDL-lowering efficacy appears largely preserved.